undamentalytics Newsletter
Sign in

Iovance Biotherapeutics, Inc. cash flow statement

In fiscal 2025, Iovance Biotherapeutics, Inc.'s operations generated −$302m of cash; it spent $33.8m on capital projects, leaving free cash flow of −$336m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−49−18−33−79−101−362−353−302−264
Depreciation and amortisation00111112111325
Stock-based pay349191220631106247
Capital spending02121122113432
Free cash flow−47−20−34−80−102−384−364−336−296
Free cash flow after stock pay−63−28−53−92−122−447−474−398−343
Shares issued732689654399463397306292

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ARVN vs IOVAADPT vs IOVAIOVA vs VCEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Iovance Biotherapeutics, Inc.